Bristol-Myers Squibb Co. (BMY)
Analysis of Revenues
Accounting Policy on Revenue Recognition
Effective January 1, 2018, BMS adopted ASC 606 using the modified retrospective method.
Source: 10-K (filing date: 2019-02-25).
Revenues as Reported
Bristol-Myers Squibb Co., Income Statement, Revenues
US$ in millions
|12 months ended||Dec 31, 2018||Dec 31, 2017||Dec 31, 2016||Dec 31, 2015||Dec 31, 2014|
|Revenues||Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).||Bristol-Myers Squibb Co.’s revenues increased from 2016 to 2017 and from 2017 to 2018.|